BIOSYNTH
Biosynth, a supplier of critical raw materials to the life science industry, announces today that it has acquired Cambridge Research Biochemicals (“CRB”), a leading independent producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors.
CRB brings a wealth of expertise to Biosynth’s peptide division, which has existing operations in the US and the Netherlands. This includes leading expertise in complex peptide chemistry and fluorescent dye labelling. CRB also brings additional custom antibody capacity in Europe, to support customers through the generation of novel, complex or unusual mono- and poly-clonal antibodies unavailable in catalogs.
Dr. Urs Spitz, CEO and President of Biosynth, said, “CRB has a long history in the peptide and antibody field, and we are excited to welcome their highly skilled team to our growing peptide division. Having a network of peptide sites at key locations, staffed by industry experts, allows us to best serve our customers throughout research and development and with the most complex and labelled peptides and high quality antibodies.”
“We are excited to be joining the Biosynth family”, added Emily Humphrys, Managing Director of Cambridge Research Biochemicals. “As one of the longest established peptide companies, we have over 40 years of experience and are proud to have a strong track record for peptide and antibody excellence with our customers. We see great similarities in the approach that Biosynth already take in leading with science and customer focus.”
--ends--
About Biosynth
Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing and distribution facilities. Supplying the pharmaceutical, life science and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at www.biosynth.com.
About Cambridge Research Biochemicals
Cambridge Research Biochemicals (www.crbdiscovery.com) is a leading independent producer of custom-made peptide and antibody tools, supplying researchers in the pharmaceutical, life science and academic sectors worldwide. The primary applications of its products are as custom-made, laboratory scale reagents for proof of principal studies within early phase drug discovery and to support biomarker programmes in clinical studies. The company produces all flavours of peptides from simple to modified, stable and radio-labelled to dye labelled from milligrams to gram-scale to the highest levels of purity. In addition, CRB is a recognised expert at generating highly specific and targeted antibodies (both polyclonal and monoclonal). Fluorescent dye labelling is also a focus.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005621/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Siren Secures Investment to Advance AI-Driven Investigations for National Security2.12.2025 10:30:00 CET | Press release
Decade-Long Partnership Expands Unified Platform For Agencies To Combat Complex Threats Siren, the all-in-one investigation company, today announced a strategic investment from Elastic (NYSE: ESTC), the company behind Elasticsearch. The investment deepens a decade-long partnership between the two companies and accelerates development of Siren’s AI-driven platform, including Siren’s newly launched K9 AI Companion, used by national security, law enforcement, and financial crime agencies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202354147/en/ Siren, the all-in-one investigation company, today announced a strategic investment from Elastic (NYSE: ESTC), the company behind Elasticsearch. The partnership combines the Elasticsearch Platform, which delivers real-time search, retrieval and anomaly detection across structured, unstructured, and streaming data, with Siren’s patented investigative intelligence technolo
P.I. Works Drives Stronger Network Results for Beeline Uzbekistan2.12.2025 10:00:00 CET | Press release
P.I. Works celebrates the success of its long-time client Beeline Uzbekistan, recognized by independent global analytics firms Opensignal and Ookla for excellence in mobile network performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202914682/en/ P.I. Works Drives Stronger Network Results for Beeline Uzbekistan Opensignal named Beeline Uzbekistan the country’s Fastest Mobile Internet provider and Most Consistent Mobile Network for the first half of 2025, while Ookla recognized the operator with the Best Mobile Video Experience award. These honors reflect the measurable impact of P.I. Works’ AI-driven automation, analytics, and optimization capabilities, combined with Beeline Uzbekistan’s strong commitments to investment and innovation. Partnership Powering Network Excellence A joint strategy to bring intelligence and efficiency into operations fuels this success. With automation, self-organizing capabilities, and
GMA with MOVIVA®: setting new standards in endoscopic bariatric treatment2.12.2025 09:59:00 CET | Press release
The innovative approach works from the inside of the stomach to help reduce hunger and to support weight loss Just a few months after the world’s first Gastric Mucosal Ablation (GMA) case using MOVIVA® at the Policlinico Universitario Agostino Gemelli in Rome, clinical experience is rapidly expanding across Europe. With around 80 procedures performed within a short timeframe in eight countries, MOVIVA® is helping to establish a new era of endoscopic bariatric treatment – offering a less invasive option as obesity rates continue to rise worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202355726/en/ GMA with MOVIVA® A promising alternative for bariatric patients: GMA with MOVIVA® GMA is an incisionless, minimally invasive endoscopic procedure. It targets the gastric fundus, the main site of ghrelin production – the so-called hunger hormone. By reducing ghrelin levels, patients experience less hunger. At the same ti
Hanshow Achieves SOC 2 Type II and SOC 3 Certifications, Elevating Data Security Standards for Global Retailers2.12.2025 09:53:00 CET | Press release
Hanshow, a global leader in digital retail solutions, announced that its All-Star digital solution has earned SOC 2 Type II and SOC 3 certifications following an independent audit by Deloitte. These internationally recognized certifications underscore Hanshow’s commitment to robust data security, privacy protection, and operational reliability for retailers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201803690/en/ All-Star of Hanshow has earned SOC 2 Type II certification. The SOC 2 and SOC 3 certifications, established by the American Institute of Certified Public Accountants (AICPA), are trusted global standards for evaluating information security, processing integrity, confidentiality, and privacy across technology service organizations. SOC 2 Type II certification assesses the operational effectiveness of security controls over an extended period, while SOC 3, as its public summary, offers customers clea
Klarna Launches Tap to Pay for In-Store Purchases Across 14 Markets2.12.2025 09:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, today launches the brand new feature Tap to Pay across 14 European markets, bringing flexible payments into physical retail at scale and transforming the Klarna app into an everyday contactless wallet. With more than 80% of European shopping still happening in physical stores, Tap to Pay brings consumers the ease of online shopping into the bricks and mortar stores. Instead of hunting for cards or juggling apps, everything sits in one place — the Klarna app — making every purchase smoother from start to finish. Utilising NFC technology, Tap to Pay turns the Klarna app into a contactless wallet, letting consumers set up a flexible payment plan and pay with a tap, all in one place – without adding their card to another wallet or switching apps at checkout. Tap to Pay builds on the rapid global uptake of the new debit-first Klarna Card, now used by more than 4 million consumers. The card is debit by default, with the option t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom